Antidiabetic agent 9
Antidiabetic agent 9 is an orally active antidiabetic agent. Antidiabetic agent 9 promotes the translocation of GLUT4 to the cell surface, activates the AMPK signaling pathway, and has no effect on the PI-3-K/AKT signaling pathway. Antidiabetic agent 9 reduces blood glucose levels in Streptozotocin (HY-13753)-induced diabetic rats. Antidiabetic agent 9 can be used in the research of diabetes.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C29H29ClN4O5
- 分子量:549.02
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
AMPK アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
GLUT4 |
体外実験
Antidiabetic agent 9 (Compound 6c) (5-25 μM; 16 h) stimulates GLUT4 translocation to the cell surface in differentiated L6-GLUT4myc myotubes in a concentration-dependent manner, with a 1.64-fold increase at 10 μM[1].
Antidiabetic agent 9 (10 μM; 16 h) activates AMPK signaling via increased phosphorylation of AMPKα at Thr-172 in differentiated L6-GLUT4myc myotubes, and this activation is suppressed by dorsomorphin[1].
Antidiabetic agent 9 (10 μM; 16 h) increases GLUT4 mRNA expression in differentiated L6 myotubes without affecting AKT2 or IRS1 mRNA levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:differentiated L6 rat skeletal muscle myotubes
-
Concentration:10 μM
-
Incubation Time:16 h
-
Result:Increased GLUT4 mRNA expression relative to control.
Left mRNA expression levels of AKT2 and IRS1 unchanged.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 160 g, streptozotocin-induced diabetic)[1]
-
Dosage:100 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced blood glucose levels by 23.9% 5 hours post-treatment.
Significantly lowered the area under the blood glucose vs. time curve (AUC) compared to the diabetic control group.
化学情報
-
分子量 549.02
-
分子式 C29H29ClN4O5
-
SMILES
ClC1=CC(N2C(NC(C(C3C4=CC=CO4)=C(C)NC5=C3C(CC(C)(C)C5)=O)=O)=C(C(OCC)=O)C=N2)=CC=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)